We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
PharmAust is a biotechnology business based in Australia. PharmAust shares (PAA) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. PharmAust has a trailing 12-month revenue of around $3.7 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Long-term investing
| 52-week range | $0.081 - $0.12 |
|---|---|
| 50-day moving average | $0.1 |
| 200-day moving average | $0.095 |
| Target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.004 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.115
| 1 week (2022-01-10) | 9.52% |
|---|---|
| 1 month (2021-12-17) | 26.37% |
| 3 months (2021-10-15) | 22.34% |
| 6 months (2021-07-16) | 22.34% |
| 1 year (2021-01-15) | 16.16% |
|---|---|
| 2 years (2020-01-17) | 29.21% |
| 3 years (2019-01-17) | 209.14% |
| 5 years (2017-01-17) | 130.46% |
| Revenue TTM | $3.7 million |
|---|---|
| Gross profit TTM | $3.4 million |
| Return on assets TTM | -7.33% |
| Return on equity TTM | -15.37% |
| Profit margin | -36.57% |
| Book value | 0.028 |
| Market capitalisation | $36.4 million |
TTM: trailing 12 months
We're not expecting PharmAust to pay a dividend over the next 12 months.
PharmAust 's shares were split on a 1:20 basis on 29 October 2015. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your PharmAust shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for PharmAust shares which in turn could have impacted PharmAust 's share price.
Over the last 12 months, PharmAust 's shares have ranged in value from as little as $0.081 up to $0.12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while PharmAust 's is 0.6479. This would suggest that PharmAust 's shares are less volatile than average (for this exchange).
PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for humans and animals. The company develops drugs for the treatment of various cancers, and viral and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug for the treatment of cancer. PharmAust has completed Phase 1 clinical trials with monepantel in human and dog diagnosed with solid tumors, as well as initiated a Phase 2 pilot study in dogs diagnosed with Lymphoma. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. The company has a research agreement with the Walter and Eliza Hall Institute to investigate the effects of MPL upon human T-lymphotrophic virus-1 (HTLV-1) infections in vitro. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.
Rapid antigen tests are proving extremely hard to find, but there are options if you can be patient trying to find a RAT.
RAQ Apparel founder Sophia Argyropoulos chats the inspo for Abbie Chatfield swimwear collab and the secret to finding the perfect bikini.
With a 100,000 bonus Membership Rewards offer and complimentary Qantas Business Rewards membership, is this the right card for your business?
Liverpool and Arsenal battle for a place in the League Cup final.
You can easily elevate your binge-watching game in the New Year.
He believes in peace at any cost – no matter how many people he has to kill to get it.
Both Melbourne teams are fighting for their seasons as we embark on derby number 2
From clean beauty to bedazzled everything, these are the makeup looks will take over 2022 and the products you need to pull them off.
Not all tests are created equal here are the different brands compared.
